Thalidomide-O-amido-C6-NH2 is primarily utilized in the development of targeted cancer therapies, particularly in the design of Proteolysis Targeting Chimeras (PROTACs). These molecules are engineered to selectively degrade disease-causing proteins by recruiting E3 ubiquitin ligases, leading to their ubiquitination and subsequent proteasomal degradation. This approach holds promise in treating various cancers, especially those resistant to conventional therapies. Additionally, it is explored in immunomodulatory applications, where it may help regulate immune responses in autoimmune diseases or inflammatory conditions. Its structure allows for conjugation with other molecules, enhancing specificity and efficacy in drug delivery systems.